Ubiquitin-like protein 3 (UBL3) is required for MARCH ubiquitination of major histocompatibility complex class II and CD86

We thank the Antibody Services Facility and Genomics Hub (Walter and Eliza Hall Institute) for the provision of reagents and expert assistance. We acknowledge the Melbourne Cytometry Platform from the Bio21 Institute node (University of Melbourne) for the provision of flow cytometry services. We acknowledge the Melbourne Mass Spectrometry and Proteomics Facility of the Bio21 Molecular Science and Biotechnology Institute at the University of Melbourne for the support of mass spectrometry analysis. We thank Satoshi Ishido (Hyogo College of Medicine, Nishinomiya, Japan) for providing the Marchf1-/- and Marchf8-/- mice. The generation of Ubl3-/- mice by CRISPR/Cas9 was performed by Andrew Kueh and Marco Herold (WEHI MAGEC laboratory). This work was supported by National Health and Medical Research Council, Australia grants and fellowships (1058193, 1154502, 1113293, and 1163090 [to J.A.V.], 1161101 and 1129672 [to J.D.M.], 2003192 [to H.E.G.McW], GNT1132604 [to A.F.H.], 1159658, 1186575, and 1156095 [to M.J.H.], and 1142358 [to M.H.L.]), Australian Research Council, Department of Education and Training grants or fellowships (110101383, 190102213, 170102471, 160103134 [to J.A.V.] and 190101242, 180100844, 160101373, and 180100521 [to J.D.M.], DE180100418 [to L.E.-M.]), the Leukemia and Lymphoma Society of America (LLS SCOR 7015-18 to M.J.H.), the Cancer Council of Victoria (1147328 and 2021 Grant In Aid to M.J.H.), and a Human Frontiers Science Program grant (0064/2011 [to J.A.V.]).